July 21, 2021 7:46am
The Biostage Chronicles: WHY the “push/promote”; it is to exercise $2.00 warrants adding more unregistered shares to the gigantic “outstanding” which is BSTG’s ONLY vehicle to raise money for operation continuation – they’re BROKE – so the only runway access is what?
News: bluebird bio (BLUE); the European Commission (EC) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel, Lenti-D™), a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen (HLA)-matched sibling hematopoietic (blood) stem cell (HSC) donor is not available.
Pre-open indications: 3 BUYs: BLUE, CRSP, GBT; 1 SELL: SGMO; SELL into Strength: AGTC, ALNY, NTLA, SAGE; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
I challenge the status quo to achieve what most believe is impossible, each session breaking down tactical ways to earn
Dow futures are UP +0.34% (+118 points), S&P futures are UP +0.18% (+8 point) and NASDAQ futures are DOWN -0.19% (-28 points)
U.S. stock futures are slipping and mixed in early premarket trading on Wednesday
European stocks rose on upbeat sentiment
Asia Pacific stocks were mixed as South Korea dived
Henry’omics:
Yesterday, on Tuesday, stocks rebounded sharply from Monday’s sell-off triggered by a Covid-inspired global growth scare. Or so they say – I believe more of an explanation needed as to Washington, DC’s conflagration of managing the coming economic opportunity.
- The Nasdaq Composite rose 1.6% while the small-cap benchmark Russell 2000 surged 3% as reopening plays popped.
Earnings: Johnson & Johnson (JNJ) gave a boost to sentiment after the drugmaker reported better than expected Q2 earnings and revenue and also raised its 2021 guidance. The shares gained about 1% in premarket trading.
Tuesday’s evening’s recap: “shaping a tradeable bottom which will also leads to an algorithmic hack to rising share pricing while blaming too much on COVID-19” … https://www.regmedinvestors.com/articles/12011
- The Nasdaq closed UP +223.89 points (+1.57%);
- The IBB closed up +1.42% and XBI closed up +2.31%;
- Sector volume was LOW with 5 of the 29-upside having higher than the 3-month average volume with very LOW volume of 1 of 4-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -2.77 points or -12.31% at 19.73;
- Tuesday’s percentage (%) of the 29-upside were +1.36% (SAGE) to +11.71% (MDXG) while the 4-downside ranges from -0.26% (GBT) to -2.22% (PSTI);
Q3/21: 4 positive, 1 holiday and 9 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?
Biostage (BSTG) closed flat at $1.70 with 49 shares traded after Monday’s +$0.01 to $1.71 with 307 shares traded.
Question#1: WHAT is the end game or play-book for this company, it has not done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
SELL into strength:
Applied Genetic Technologies (AGTC) closed up +$0.33 to $3.92 and has a positive +$0.03 or -0.77% pre-market indication.
Alnylam Pharmaceuticals (ALNY) closed up +$7.86 to $183.17 and “had” a negative -$46.76 or -25.53% aftermarket indication – weird or mixed numbers with NO pre-market indication?
Intellia Therapeutics (NTLA) closed up again +$7.18 to $146.12 after Monday’s+$3.69 to $138.94 after Friday’s -$2.85 to $135.25 and has a positive +$0.99 or +0.68% pre-market indication.
Sage Therapeutics (SAGE) closed up +$0.63 to $46.89 after Monday’s -$1.48 to $48.26 and Friday’s $47.74 with a positive +$0.11 or +0.23% pre-market indication.
BUY:
bluebird bio (BLUE) closed up +$0.69 to $27.33 after Monday’s $26.64 and last Friday’s $26.78 with a positive +$0.82 or +3% pre-market.
CRISPR therapeutics (CRSP) closed down again -$1.59 to $124.14 after Monday’s -$0.52 to $125.73 after Friday’s -$0.85 to $126.25 and has a positive +$2.64 or +2.13% aftermarket indication.
Global Blood Solutions (GBT) closed down -$0.08 to $30.60 after Monday’s $30.68 and last Friday’s $31.87 with a positive +$0.64 or +2.09% pre-market indication.
SELL:
Sangamo Therapeutics (SGMO) closed up +$0.36 to $10.17 after Monday’s $9.81 and Friday’s $9.82 with a negative -$0.35 or -3.44% aftermarket indication
The BOTTOM LINE: Volatility is still front-and-center in the sector …
I also continue to be a skeptic yet; the sustainability of Tuesday’s price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call
A market move dragged many of the cell and gene therapy equities back to a positive upside; however, the cell and gene therapy sector is still a bit confusing as sentiment rages and fades, momentum is burped and usurped as fundamentals seem ignored.
I also think what we’ve seen here are the early warning shots of a correction that we’ll see probably... in late August or September,” and I agree with Matt Maley, equity strategist at Miller Tabak.
Q2 earnings LPS (loss-per-share) release date are soon to be divulged and not positively; yet another – Sage Therapeutics (SAGE) releases “earnings” on 8/3 and MiMedx (MDXG), AxoGen (AXGN) on 8/4 and Athersys ATHX) on 8/9
It takes courage to not being discouraged by “our” universe of cell and gene therapy equities or sector.
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
